Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • US government seeks...

    US government seeks part of Oklahoma $270 million opioid settlement

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-30T09:00:50+05:30  |  Updated On 30 Jun 2019 9:00 AM IST
    US government seeks part of Oklahoma $270 million opioid settlement

    It's not clear how much of the state's settlement the federal government is seeking or where the money would come from. Oklahoma's settlement in March with Purdue, the maker of OxyContin, and the company's controlling family called for nearly $200 million to go into a trust for the creation of a National Center for Addiction Studies and Treatment at Oklahoma State University in Tulsa.


    OKLAHOMA CITY: The U.S. government wants a portion of Oklahoma's $270 million settlement with Purdue Pharma that stemmed from the state's ongoing lawsuit against opioid makers.


    The U.S. Centers for Medicare and Medicaid Services wrote to the head of Oklahoma's Medicaid agency that it has determined the federal government is entitled to part of Oklahoma's proceeds.


    The June 12 letter from CMS' regional director Bill Brooks also seeks detailed information from the Oklahoma Health Care Authority and warns that failure to return a portion of the settlement money could result in the withholding of federal funds. Medicaid is jointly funded by the federal government and states.


    Details of the letter were first reported Thursday by The Washington Post.


    Read Also: Opioid use booming as tramadol crisis emerges in Africa- UN drug report


    The Oklahoma Health Care Authority requested a 90-day extension from CMS to provide the federal agency with the requested information, and that request was granted this week, giving the state until Oct. 12 to provide its response.


    A spokesman for Attorney General Mike Hunter says his office is reviewing the CMS request. Spokesman Alex Gerszewski also said the federal government's request won't affect state revenue.


    It's not clear how much of the state's settlement the federal government is seeking or where the money would come from. Oklahoma's settlement in March with Purdue, the maker of OxyContin, and the company's controlling family called for nearly $200 million to go into a trust for the creation of a National Center for Addiction Studies and Treatment at Oklahoma State University in Tulsa. Private attorneys who handled the case for Oklahoma received about $60 million, while an additional $12.5 million was earmarked for local governments.


    CMS says it is entitled to a portion of the funds under a provision of the federal Social Security Act that applies to money recovered by the state. A CMS spokesman says anytime the agency becomes aware of a settlement that might involve a Medicaid overpayment, the agency works with states to determine what portion may need to be returned to the federal government.


    Federal agencies requesting a portion of such money is not unprecedented. In 2015, the federal government received half of a $1.375 billion settlement agreement with the rating agency Standard & Poor's Financial Services LLC, but in that the case the U.S. Department of Justice was involved in the lawsuit, along with 19 states and the District of Columbia.


    The letter did not reference Oklahoma's $85 million settlement with Israeli-owned Teva Pharmaceuticals or the state's ongoing public nuisance lawsuit against consumer products giant Johnson & Johnson. Witnesses for the state have suggested the cost of abating the opioid crisis in Oklahoma could be as much as $17.5 billion over the next 30 years.


    Read ALso: Oklahoma judge approves Teva Pharma USD 85 million opioid settlement


    The idea the state could be on the hook to pay millions of dollars to the federal government didn't sit well with Oklahoma state Rep. Mark McBride, R-Moore.


    "As far as I'm concerned, that's the state's money," said McBride, one of several lawmakers critical of the way the Purdue settlement was structured. "It seems like the federal government is seeing that the attorney general won with these two settlements, and now they have their hand out, and I think that's just wrong."


    After the Purdue settlement was announced, the Oklahoma Legislature approved a new law clarifying that any settlement proceeds go directly into the state treasury.

    Alex GerszewskiAttorney General Mike HunterHealthcareJnJJohnsonJohnson & JohnsonOklahomaOklahoma State University TulsaOklahomasopioidopioid makersOxyContinPurdue PharmaTeva PharmUnited States
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok